No Data
No Data
Promising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential
Express News | Tenaya Therapeutics Reveals Interim Data From RIDGE Natural History And Seroprevalence Study Of Adults With PKP2-Associated ARVC At Heart Rhythm 2025
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Tenaya Therapeutics Amid Promising TN-201 Data and Financial Stability
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Trytosaveabit : Tell me you seen the great results outa BCTX Brother! Yes needs to be replicated lots! But IMO its pretty amazing so far! And if repeatable only sometimes? Could be soooo wonderful for so many!